Artivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock

Core Viewpoint - Artivion, Inc. has entered into privately negotiated exchange agreements to repurchase approximately $95 million of its 4.250% Convertible Senior Notes due 2025 in exchange for shares of its common stock, with the transaction expected to close around May 28, 2025 [1] Group 1: Exchange Agreements - The company will repurchase approximately $95 million principal amount of Existing Convertible Notes in exchange for shares of common stock, with the number of shares to be determined based on the trading price over a four-day averaging period starting May 15, 2025 [1] - At the closing stock price of $28.91, the transaction would result in the issuance of approximately 4.1 million shares [1] - Cash will also be paid to note holders for accrued and unpaid interest as part of the exchange agreements [1] Group 2: Financial Advisory - J. Wood Capital Advisors LLC acted as the financial advisor to Artivion in connection with the exchange transactions [2] Group 3: Company Overview - Artivion, Inc. is a medical device company focused on developing solutions for cardiac and vascular surgeons, particularly in treating aortic diseases [5] - The company’s product groups include aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, marketed in over 100 countries [5]